Companies/GT Biopharma, Inc.

Company profile

GT Biopharma, Inc.

NASDAQ: GTBP · Healthcare · Biotechnology

PublicHQ San Francisco, CA · San FranciscoCIK 0000109657Reports USD

#1166 of 1,422 Healthcare companies by revenue

EA Score

32D

FH 28DQ 38GM —SS 29

v0.1 · 55/100 weight · provisional

↑ balance-sheet leverage, disclosure history · ↓ workforce scale, return on equity

Methodology →

Revenue TTM

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$28.4M

Employees

as of 2026-08-23

Market cap

$9.1M

as of 2026-08-23

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$0$02020

Net income-$28.4M-$28.4M2025

Operating income-$12.4M-$12.4M2025

Total assets$8.1M$8.1M2025

Liabilities$1.3M$1.3M2025

Equity$5.8M$5.8M2025

Revenue trend

FY2012 – FY2020 · USD

$342.0k

FY12

$368.0k

FY13

$61.0k

FY14

$27.0k

FY15

FY16

FY17

FY20

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

What is GT Biopharma, Inc.’s revenue?

GT Biopharma, Inc. booked $0 in FY2020 revenue — among the slowest-growing Healthcare companies we track, at a -Infinity% net margin.

Peers · Healthcare

Integrated Cannabis Solutions, Inc.——Theriva Biologics, Inc.39D Lunai Bioworks Inc.20D PreveCeutical Medical Inc.——Revive Therapeutics Ltd.——Unidoc Health Corp.——

Neighbors

San Francisco →

Visa Inc.$40.0B86A Wells Fargo & Company$85.1B55C Salesforce, Inc.$41.5B80B+Uber Technologies, Inc.$52.0B71B Prologis, Inc.$8.8B66B Cloudflare, Inc.$2.2B59C

Key facts

CEOMichael Martin Breen

SectorHealthcare

IndustryBiotechnology

HeadquartersSan Francisco, CA

ExchangeNASDAQ: GTBP

Employees1

IPO date2018-03-27

Latest filings

8-K2026-08-14 10-Q2026-08-14 DEF 14A2026-07-02 8-K2026-06-12 8-K2026-05-22 10-Q2026-05-15 8-K2026-04-07 8-K2026-03-02

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.